"We are trying to develop epigenetic biomarkers that can predict patients that are starting to progress to neuroendocrine prostate cancer," says Jindan Yu, MD, PhD. In this video, Jindan Yu, MD, PhD, ...

Urology in the Lab: Researchers link EBV to multiple sclerosis ...

Panelists discuss how managing overactive bladder in older adults requires a holistic approach that integrates treatment of comorbidities, emerging therapeutic options, and quality-of-life ...

A panelist discusses how significant unmet needs in NMIBC treatment persist around BCG supply shortages, optimal treatment sequencing, biomarker development for patient selection, and reducing ...

Plasmacytoid urothelial carcinoma is rare and aggressive, with poor outcomes and challenges in accurate staging. National and institutional data reveal discrepancies in chemotherapy use and disease ...

CMS has selected 15 additional drugs for Medicare Part D price negotiations, aiming to lower healthcare costs for enrollees. The Inflation Reduction Act allows Medicare to negotiate drug prices, with ...

Illuccix is approved in Europe for PSMA-positive lesion detection in prostate cancer, following prior approvals in the US, Australia, and Canada. The phase 3 VISION trial showed 177Lu-PSMA-617 plus ...

Data for newer therapies have shown that more than 50% of patients with BCG-unresponsive NMIBC experience a complete response after just 3 months of treatment. What are your thoughts on these findings ...

"My biggest hope for people reading this review is to understand that there are some golden opportunities for research," says Laura Bukavina, MD, MPH, MSc. Isali: I think our review mainly highlighted ...

PSMA PET imaging can lead to significant stage migration in mHSPC, affecting treatment decisions and patient outcomes. 40.3% of patients experienced stage changes with PSMA PET, including shifts from ...

"The notion that the urine is sterile should be hopefully abolished by now, especially in this group where we know that these individuals do have a lot of bacteria growing in their bladders," says ...

The RELIEF ureteral stent is the first FDA-cleared stent for vesicoureteral reflux prevention in the US. The stent's design minimizes bladder spasms and reflux, improving patient comfort compared to ...